Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma
Abstract Background Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently emerged as predictive biomarkers of resp...
Main Authors: | Simona Serratì, Roberta Di Fonte, Letizia Porcelli, Simona De Summa, Ivana De Risi, Livia Fucci, Eustachio Ruggieri, Tommaso Maria Marvulli, Sabino Strippoli, Rossella Fasano, Tania Rafaschieri, Gabriella Guida, Michele Guida, Amalia Azzariti |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-023-02808-9 |
Similar Items
-
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
by: Simona Serratì, et al.
Published: (2022-01-01) -
Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
by: Andrea Botticelli, et al.
Published: (2021-08-01) -
Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
by: Mina Nikanjam, et al.
Published: (2022-08-01) -
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01) -
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
by: Paolo A. Ascierto, et al.
Published: (2017-08-01)